Forecasts by Type (Direct-to-Patient Marketing (DTC Prescribed Drug Advertising, Disease Awareness Campaigns, Brand Promotion, Healthcare Services Promotion, Laboratory Testing Promotion, Other), Direct-to-Patient Health Services (Tele Consultation, Drug Prescription, Medical Call Centres, Telesampling, Online Services), Direct-to-Patient Clinical Trials (Tele Health Screening, Investigational Medicinal Product (IMP), Patient Support Systems, Other), Direct-to-Patient Logistics (Prescribed Medicine Delivery, Pre-Clinical Supplies, Clinical Trial Supplies, Home Trial Support, Test Samples Collection, Rest All CSO Services)), by Therapeutics (Cardiovascular Disease, Respiratory Diseases, Oncology, Infectious Diseases, Dermatology, Other), by Model (Depot-to-Patient, Site-to-Patient, Hybrid Model, Direct-From-Patient (DfP), Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis
The Direct-to-Patient Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Industry Focus on Patient-Centricity Is Driving the Market Growth The direct-to-patient and home trial support (DtP/HTS) strategy can provide priceless assistance to patients, regardless of whether they are getting a commercial therapy that has been approved or are taking part in a clinical trial. The DtP strategy has developed over the past ten years, with global adoption expanding dramatically in the last three years, fuelled by an industry focus on patient-centricity that is becoming more intense. This strategy provides considerable benefits for the patient as well as all other parties by enabling patients to obtain individualised care, cutting-edge or well-established therapies without leaving the comfort of their own homes. Technology has changed every part of our everyday life, which makes the world feel smaller than it has ever been.
Businesses in the medical, healthcare, and pharmaceutical industries have refrained from embracing social media for a variety of reasons. Corporations welcomed it, but pharmacists baulked because they thought it would present an excessive amount of legal risk. Even so, a few forerunners in the direct-to-patient sector have prepared the way for others. They have demonstrated that, in the quickly evolving healthcare environment of today, it is not only doable but also crucial. Tens of thousands of branding exercises are sent to patients in the medical field each day.
What Questions Should You Ask before Buying a Market Research Report? • How is the direct-to-patient (DTP) market evolving? • What is driving and restraining the direct-to-patient (DTP) market? • How will each direct-to-patient (DTP) submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032? • How will the market shares for each direct-to-patient (DTP) submarket develop from 2022 to 2032? • What will be the main driver for the overall market from 2022 to 2032? • Will leading direct-to-patient (DTP) markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others? • How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032? • Who are the leading players and what are their prospects over the forecast period? • What are the direct-to-patient (DTP) projects for these leading companies? • How will the industry evolve during the period between 2022 and 2032? What are the implications of direct-to-patient (DTP) projects taking place now and over the next 10 years? • Is there a greater need for product commercialisation to further scale the direct-to-patient (DTP) market? • Where is the direct-to-patient (DTP) market heading and how can you ensure you are at the forefront of the market? • What are the best investment options for new product and service lines? • What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the direct-to-patient (DTP) market today, and over the next 10 years: • Our 344-page report provides 155 tables and 165 charts/graphs exclusively to you. • The report highlights key lucrative areas in the industry so you can target them – NOW. • It contains in-depth analysis of global, regional and national sales and growth. • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the direct-to-patient (DTP) market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal commercial prospects • In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares. • You will find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising direct-to-patient (DTP) prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Type • Direct-to-Patient Marketing • Direct-to-Patient Health Services • Direct-to-Patient Clinical Trials • Direct-to-Patient Logistics
Model • Depot-to-Patient • Site-to-Patient • Hybrid Model • Direct-From-Patient (DfP) • Other DtP Models
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:
North America • U.S. • Canada
Europe • Germany • UK • France • Italy • Spain • Rest of Europe
Asia Pacific • China • Japan • India • Australia • South Korea • Rest of Asia Pacific
MEA • Turkey • Saudi Arabia • South Africa • UAE • Rest of MEA
Latin America • Brazil • Mexico • Rest of Latin America
The report also includes profiles and for some of the leading companies in the Direct-to-Patient Market Report 2022-2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth • Access TeleCare • Agnity Inc. • AMD Global Telemedicine • American Well • Avel eCare • Axs Health • Babylon Health • Citius Tech • Dictum Health Inc. • Doctor Anywhere • Doctor on Demand • Health Partners • Health Tap • HIMS • Marken • 20/20 NOW • NURX • Practo Technologies Pvt. Ltd. • Specialists on call, Inc. • Teladoc Health Inc. • True pill • Up Script Health
Overall world revenue for Direct-to-Patient (DTP) Market, 2022 to 2032 in terms of value the market will surpass US$40,746 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Direct-to-Patient Market Report 2022-2032 report help you? In summary, our 340+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Direct-to-Patient (DTP) Market, 2022 to 2032 Market, with forecasts for type, direct-to-patient marketing, direct-to-patient health services, clinical trials, direct-to-patient logistics, therapeutics, and model, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2032 for five regional and 20 key national markets – See forecasts for the Direct-to-Patient (DTP) Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 22 of the major companies involved in the Direct-to-Patient (DTP) Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Direct-to-Patient (DTP) Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
Buy our report today Direct-to-Patient Market Report 2022-2032: Forecasts by Type (Direct-to-Patient Marketing (DTC Prescribed Drug Advertising, Disease Awareness Campaigns, Brand Promotion, Healthcare Services Promotion, Laboratory Testing Promotion, Other), Direct-to-Patient Health Services (Tele Consultation, Drug Prescription, Medical Call Centres, Telesampling, Online Services), Direct-to-Patient Clinical Trials (Tele Health Screening, Investigational Medicinal Product (IMP), Patient Support Systems, Other), Direct-to-Patient Logistics (Prescribed Medicine Delivery, Pre-Clinical Supplies, Clinical Trial Supplies, Home Trial Support, Test Samples Collection, Rest All CSO Services)), by Therapeutics (Cardiovascular Disease, Respiratory Diseases, Oncology, Infectious Diseases, Dermatology, Other), by Model (Depot-to-Patient, Site-to-Patient, Hybrid Model, Direct-From-Patient (DfP), Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1. Report Overview 1.1 Objectives of the Study 1.2 Introduction to Direct-To-Patient Market 1.3 What This Report Delivers 1.4 Why You Should Read This Report 1.5 Key Questions Answered by This Analytical Report 1.6 Who is This Report for? 1.7 Methodology 1.7.1 Market Definitions 1.7.2 Market Evaluation & Forecasting Methodology 1.7.3 Data Validation 1.7.3.1 Primary Research 1.7.3.2 Secondary Research 1.8 Frequently Asked Questions (FAQs) 1.9 Associated Visiongain Reports 1.10 About Visiongain
2 Executive Summary
3 Market Overview 3.1 Key Findings 3.2 Market Dynamics 3.2.1 Market Driving Factors 3.2.1.1 Increase in Social Media's Relevance 3.2.1.2 Direct-to-Patient Marketing Driven by Decentralization 3.2.1.3 Recognizing the Value of Direct-to-Patient 3.2.2 Market Restraining Factors 3.2.2.1 Legal restrictions Are Impeding the Expansion of the DTP Market 3.2.2.2 Development of Digital Technology Projected to Boost Industry Growth 3.2.2.3 Booming Telehealth to Fuel Market Growth 3.2.3 Market Opportunities 3.2.3.1 DTP Services Are not Just for Delivering Medications 3.2.3.2 DTP Would be the Primary Point of Contact for Patient Support 3.2.3.3 DTP's Integration into Medical Universities, Clinics, and Hospitals 3.3 Supply Chain 3.4 COVID-19 Impact Analysis 3.4.1 COVID Impact Market Analysis (V-Shaped Recovery Scenario) 3.4.2 COVID Impact Market Analysis (W-Shaped Recovery Scenario) 3.4.3 COVID Impact Market Analysis (U-Shaped Recovery Scenario) 3.4.4 COVID Impact Market Analysis (L-Shaped Recovery Scenario) 3.5 Porter’s Five Forces Analysis 3.5.1 Supplier Power 3.5.2 Buyer Power 3.5.3 Competitive Rivalry 3.5.4 Threat from Substitutes 3.5.5 Threat of New Entrants 3.6 PEST Analysis 3.6.1 Political Factors 3.6.2 Economic Factors 3.6.3 Social Factors 3.6.4 Technological Factors
4 Direct-to-Patient Market Analysis by Type 4.1 Key Findings 4.2 Type Segment: Market Attractiveness Index 4.3 Direct-to-Patient Marketing 4.4 Direct-to-Patient Health Services 4.5 Direct-to-Patient Clinical Trials 4.6 Direct-to-Patient Logistics 4.7 Direct-To-Patient Market by Type
5 Direct-To-Patient Market Analysis by Marketing 5.1 Key Findings 5.2 Marketing Segment: Market Attractiveness Index 5.3 DTC Prescribed Drug Advertising 5.4 Disease Awareness Campaigns 5.5 Brand Promotion 5.6 Healthcare Services Promotion 5.7 Laboratory Testing Promotion 5.8 Other Direct-to-Patient Marketing 5.9 Direct-to-Patient Market by Marketing
6 Direct-to-Patient Market Analysis by Direct-to-Patient Health Services 6.1 Key Findings 6.2 Direct-to-Patient Health Services Segment: Market Attractiveness Index 6.3 Tele Consultation 6.4 Drug Prescription 6.5 Medical Call Centers 6.6 Telesampling 6.7 Online Services 6.8 Direct-to-Patient Market by Health Service
7 Direct-to-Patient Market Analysis by Clinical Trials 7.1 Key Findings 7.2 Clinical Trials Segment: Market Attractiveness Index 7.3 Tele Health Screening 7.4 Investigational Medicinal Product (IMP) 7.5 Patient Support Systems 7.6 Other Clinical Trial Services 7.7 Direct-to-Patient Market by Clinical Trials
8 Direct-to-Patient Market Analysis by Direct-to-Patient Logistics 8.1 Key Findings 8.2 Direct-to-Patient Logistics Segment: Market Attractiveness Index 8.3 Prescribed Medicine Delivery 8.4 Pre-Clinical Supplies 8.5 Clinical Trial Supplies 8.6 Home Trial Support 8.7 Test Samples Collection 8.8 Direct-to-Patient Market by Logistics
9 Direct-to-Patient Market Analysis by Therapeutics 9.1 Key Findings 9.2 Therapeutics Segment: Market Attractiveness Index 9.3 Cardiovascular Diseases 9.4 Respiratory Diseases 9.5 Oncology 9.6 Infectious Diseases 9.7 Dermatology 9.8 Other Therapeutics 9.9 Direct-to-Patient Market by Therapeutics 10 Direct-to-Patient Market Analysis by Model 10.1 Key Findings 10.2 Model Segment: Market Attractiveness Index 10.3 Site-to-Patient 10.4 Hybrid Model 10.5 Direct-From-Patient (DfP) 10.6 Other DtP Models 10.7 Direct-to-Patient Market by Model
11 Direct-to-Patient Market Analysis by Region 11.1 Key Findings 11.2 Direct-to-Patient Market Attractiveness Index by Region 11.3 Direct-to-Patient Market Forecast 11.4 Direct-to-Patient Market by Region
12 North America Direct-To-Patient Market Analysis 12.1 Key Findings 12.2 Growing Desire for In-Home Care 12.3 Multinational DtP Company Presence in the Region 12.4 North America Direct-To-Patient Market Attractiveness Index by Region 12.5 Direct-to-Patient Market by Value 12.6 North America Direct-to-Patient Market by Marketing 12.7 North America Direct-to-Patient Market by Health Services 12.8 North America Direct-to-Patient Market by Clinical Trials 12.9 North America Direct-to-Patient Market by Logistics 12.10 North America Direct-to-Patient Market by Therapeutics 12.11 North America Direct-to-Patient Market by Model 12.12 North America Direct-to-Patient Market by Country 12.13 U.S. Direct-to-Patient Market Analysis 12.13.1 Rising Healthcare Costs Are Anticipated to Accelerate the Uptake of Telehealth 12.13.2 U.S. Laws for DTP Businesses 12.14 Canada Direct-to-Patient Market Analysis 12.14.1 Increasing Preference for Remote and Home Monitoring
13 Europe Direct-To-Patient Market Analysis 13.1 Key Findings 13.2 Significant Investment in Clinical Research Infrastructure 13.3 How DtP Supports Clinical Trial Innovation? 13.4 Europe Direct-to-Patient Market Attractiveness Index by Region 13.5 Europe Direct-to-Patient Market by Value 13.6 Europe Direct-to-Patient Market by Type 13.7 Europe Direct-to-Patient Market by Marketing 13.8 Europe Direct-to-Patient Market by Health Services 13.9 Europe Direct-to-Patient Market by Clinical Trials 13.10 Europe Direct-to-Patient Market by Logistics 13.11 Europe Direct-to-Patient Market by Therapeutics 13.12 Europe Direct-to-Patient Market by Model 13.13 Europe Direct-to-Patient Market by Country 13.14 Germany Direct-To-Patient Market Analysis 13.14.1 Germany's DTP Market Growing Due to Good Health Reimbursement Policies 13.14.2 Numerous Telemedicine Systems Are Now in Use 13.15 U.K. Direct-To-Patient Market Analysis 13.15.1 Hospital-based Care Trend Shifting to Home Care 13.15.2 Ageing Population Will Bring Opportunities for DTP 13.16 France Direct-To-Patient Market Analysis 13.16.1 Significant Fragmentation in the Direct-to-Patient Services Market 13.17 Italy Direct-to-Patient Market Analysis 13.17.1 Quality and Effectiveness of the Italian Healthcare System Can Occasionally Be Criticised 13.17.2 Laws Concerning the Delivery of DTP Services 13.18 Spain Direct-To-Patient Market Analysis 13.18.1 The Healthcare System in Spain is Among the Best in the World 13.19 Rest of Europe Direct-To-Patient Market Analysis
14 Asia-Pacific Direct-To-Patient Market Analysis 14.1 Key Findings 14.2 Growing Health Consumerism 14.3 A Shift in Stakeholder Confidence 14.4 Asia Pacific Direct-to-Patient Market Attractiveness Index by Region 14.5 Asia Pacific Direct-to-Patient Market by Value 14.6 Asia Pacific Direct-to-Patient Market by Type 14.7 Asia Pacific Direct-to-Patient Market by Marketing 14.8 Asia Pacific Direct-to-Patient Market by Health Services 14.9 Asia Pacific Direct-to-Patient Market by Clinical Trials 14.10 Asia Pacific Direct-to-Patient Market by Logistics 14.11 Asia Pacific Direct-to-Patient Market by Therapeutics 14.12 Asia Pacific Direct-to-Patient Market by Model 14.13 Asia Pacific Direct-to-Patient Market by Country 14.14 China Direct-to-Patient Market Analysis 14.14.1 Government Made "Direct-To-Patients" Shipment of Investigational Drugs Mandatory 14.15 India Direct-to-Patient Market Analysis 14.15.1 Country's Healthcare System is Transitioning to the DtP Model 14.15.2 Telemedicine in India 14.16 Japan Direct-to-Patient Market Analysis 14.16.1 DtP Services Are Becoming More Popular in Japan 14.16.2 Close Patient Engagement is a Majorly Emerging Sector for Japanese Pharma 14.17 Australia Direct-to-Patient Market Analysis 14.17.1 Australian Government Offers Packages for Home Care Package (HCP) 14.17.2 Remarkable Growth of Australia's Market for Direct-To-Patient 14.18 South Korea Direct-to-Patient Market Analysis 14.19 Rest of Asia-Pacific Direct-to-Patient Market Analysis
15 Latin America Direct-To-Patient Market Analysis 15.1 Key Findings 15.2 Latin America Direct-to-Patient Market Attractiveness Index by Region 15.3 Latin America Direct-To-Patient Market by Value 15.4 Latin America Direct-To-Patient Market by Type 15.5 Latin America Direct-To-Patient Market by Marketing 15.6 Latin America Direct-To-Patient Market by Health Services 15.7 Latin America Direct-To-Patient Market by Clinical Trials 15.8 Latin America Direct-To-Patient Market by Logistics 15.9 Latin America Direct-To-Patient Market by Therapeutics 15.10 Latin America Direct-To-Patient Market by Model 15.11 Latin America Direct-To-Patient Market by Country 15.12 Brazil Direct-to-Patient Market Analysis 15.12.1 Government Policies for the DTP Industry 15.13 Mexico Direct-to-Patient Market Analysis 15.14 Rest of Latin America Direct-to-Patient Market Analysis
16 MEA Direct-To-Patient Market Analysis 16.1 Key Findings 16.2 MEA Direct-to-Patient Market Attractiveness Index by Region 16.3 MEA Direct-To-Patient Market by Value 16.4 MEA Direct-To-Patient Market by Type 16.5 MEA Direct-To-Patient Market by Marketing 16.6 MEA Direct-To-Patient Market by Health Services 16.7 MEA Direct-To-Patient Market by Clinical Trials 16.8 MEA Direct-To-Patient Market by Logistics 16.9 MEA Direct-To-Patient Market by Therapeutics 16.10 MEA Direct-To-Patient Market by Model 16.11 MEA Direct-To-Patient Market by Country 16.12 Saudi Arabia Direct-to-Patient Market Analysis 16.12.1 Saudi Arabia Government is Developing and Improving Healthcare Services Through a Transformation Plan 16.13 Turkey Direct-to-Patient Market Analysis 16.13.1 Direct To Patient Has a Large Distribution Network that Reaches All Regions of Turkey 16.13.2 Turkey’s Family Medicine Reform Will Boost Demand for DtP Services in Nearing Future 16.14 UAE Direct-to-Patient Market Analysis 16.14.1 Rise in Healthcare Demand in the United Arab Emirates 16.14.2 UAE is Moving Toward DtP and Telehealth Models 16.15 South Africa Direct-to-Patient Market Analysis 16.15.1 Professional Training is Required for DtP Service Providers 16.15.2 Patient's Cultural and Family Context at Home Must Include Professional DTP 16.16 Rest of MEA Direct-to-Patient Market Analysis 16.16.1 Start-Ups in the Nation Could Destabilise the DTP Market
17 Competitive Landscape 17.1 Key Business Strategy Analysis- Agreement 17.2 Key Business Strategy Analysis- Contract 17.3 Key Business Strategy Analysis- Expansion 17.4 Key Business Strategy Analysis- Partnership 17.5 Key Business Strategy Analysis- Launch
18 Company Profiles 18.1 Access TeleCare 18.1.1 Company Snapshot 18.1.2 Company Overview 18.1.3 Product Benchmarking 18.1.4 Strategic Outlook 18.2 Agnity Inc. 18.2.1 Company Snapshot 18.2.2 Company Overview 18.2.3 Product Benchmarking 18.2.4 Strategic Outlook 18.3 AMD Global Telemedicine 18.3.1 Company Snapshot 18.3.2 Company Overview 18.3.3 Product Benchmarking 18.3.4 Strategic Outlook 18.4 American Well 18.4.1 Company Snapshot 18.4.2 Company Overview 18.4.3 Financial Analysis 18.4.3.1 Net Revenue, 2018-2021 18.4.3.2 Operating Income, 2018-2021 18.4.3.3 Research & Development Expenses, 2018-2021 18.4.4 Product Benchmarking 18.4.5 Strategic Outlook 18.5 Avel eCare 18.5.1 Company Snapshot 18.5.2 Company Overview 18.5.3 Product Benchmarking 18.5.4 Strategic Outlook 18.6 Axs Health 18.6.1 Company Snapshot 18.6.2 Company Overview 18.6.3 Product Benchmarking 18.6.4 Strategic Outlook 18.7 Babylon Health 18.7.1 Company Snapshot 18.7.2 Company Overview 18.7.2.1 Net Revenue, 2019-2021 18.7.2.2 Operating Income, 2019-2021 18.7.2.3 R&D Expenses, 2019-2021 18.7.3 Product Benchmarking 18.7.4 Strategic Outlook 18.8 Citius Tech 18.8.1 Company Snapshot 18.8.2 Company Overview 18.8.3 Product Benchmarking 18.8.4 Strategic Outlook 18.9 Dictum Health Inc. 18.9.1 Company Snapshot 18.9.2 Company Overview 18.9.3 Product Benchmarking 18.9.4 Strategic Outlook 18.10 Doctor Anywhere 18.10.1 Company Snapshot 18.10.2 Company Overview 18.10.3 Product Benchmarking 18.10.4 Strategic Outlook 18.11 Doctor on Demand 18.11.1 Company Snapshot 18.11.2 Company Overview 18.11.3 Product Benchmarking 18.11.4 Strategic Outlook 18.12 Health Partners 18.12.1 Company Snapshot 18.12.2 Company Overview 18.12.3 Financial Analysis 18.12.3.1 Net Revenue, 2018-2020 18.12.3.2 Operating Income, 2018-2020 18.12.4 Product Benchmarking 18.12.5 Strategic Outlook 18.13 Health Tap 18.13.1 Company Snapshot 18.13.2 Company Overview 18.13.3 Product Benchmarking 18.13.4 Strategic Outlook 18.14 HIMS 18.14.1 Company Snapshot 18.14.2 Company Overview 18.14.3 Financial Analysis 18.14.3.1 Net Revenue, 2019-2021 18.14.3.2 Operating Income, 2019-2021 18.14.4 Product Benchmarking 18.14.5 Strategic Outlook 18.15 Marken 18.15.1 Company Snapshot 18.15.2 Company Overview 18.15.3 Product Benchmarking 18.15.4 Strategic Outlook 18.16 20/20 NOW 18.16.1 Company Snapshot 18.16.2 Company Overview 18.16.3 Product Benchmarking 18.16.4 Strategic Outlook 18.17 NURX 18.17.1 Company Snapshot 18.17.2 Company Overview 18.17.3 Product Benchmarking 18.17.4 Strategic Outlook 18.18 Practo Technologies Pvt. Ltd 18.18.1 Company Snapshot 18.18.2 Company Overview 18.18.3 Product Benchmarking 18.18.4 Strategic Outlook 18.19 Specialists on call, Inc 18.19.1 Company Snapshot 18.19.2 Company Overview 18.19.3 Financial Analysis 18.19.3.1 Net Revenue, 2019-2021 18.19.3.2 Research & Development Expense, 2019-2021 18.19.4 Product Benchmarking 18.19.5 Strategic Outlook 18.20 Teladoc Health Inc 18.20.1 Company Snapshot 18.20.2 Company Overview 18.20.3 Financial Analysis 18.20.3.1 Net Revenue, 2017-2021 18.20.3.2 Operating Income, 2017-2021 18.20.3.3 Research & Development Expenses, 2017-2021 18.20.4 Product Benchmarking 18.20.5 Strategic Outlook 18.21 True pill 18.21.1 Company Snapshot 18.21.2 Company Overview 18.21.3 Product Benchmarking 18.21.4 Strategic Outlook 18.22 Up Script Health 18.22.1 Company Snapshot 18.22.2 Company Overview 18.22.3 Product Benchmarking 18.22.4 Strategic Outlook
19 Conclusion and Recommendations 19.1 Concluding Remarks from Visiongain 19.2 Recommendations for Market Players
List of Tables Table 1 Direct-to-Patient Market Snapshot, 2022 & 2032 (US$ million, CAGR %) Table 2 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (V-Shaped Recovery Scenario) Table 3 Direct-to-Patient Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (V-Shaped Recovery Scenario) Table 4 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (W-Shaped Recovery Scenario) Table 5 Direct-to-Patient Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (W-Shaped Recovery Scenario) Table 6 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (U-Shaped Recovery Scenario) Table 7 Direct-to-Patient Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (U-Shaped Recovery Scenario) Table 8 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (L-Shaped Recovery Scenario) Table 9 Direct-to-Patient Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (L-Shaped Recovery Scenario) Table 10 Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 11 Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 12 Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 13 Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 14 Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 15 Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 16 Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 17 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 18 Direct-to-Patient Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 19 North America Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 20 North America Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 21 North America Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 22 North America Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 23 North America Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 24 North America Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 25 North America Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 26 North America Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 27 U.S. Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 28 Canada Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 29 Europe Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 30 Europe Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 31 Europe Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 32 Europe Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 33 Europe Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 34 Europe Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 35 Europe Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 36 Europe Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 37 Europe Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 38 Germany Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 39 UK Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 40 France Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 41 Italy Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 42 Spain Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 43 Rest of Europe Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 44 Asia-Pacific Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 45 Asia-Pacific Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 46 Asia-Pacific Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 47 Asia-Pacific Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 48 Asia-Pacific Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 49 Asia-Pacific Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 50 Asia-Pacific Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 51 Asia-Pacific Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 52 Asia-Pacific Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 53 China Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 54 India Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 55 Japan Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 56 Australia Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 57 South Korea Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 58 Rest of Asia-Pacific Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 59 Latin America Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 60 Latin America Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 61 Latin America Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 62 Latin America Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 63 Latin America Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 64 Latin America Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 65 Latin America Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 66 Latin America Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 67 Latin America Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 68 Brazil Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 69 Mexico Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 70 Rest of Latin America Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR(%)) Table 71 MEA Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 72 MEA Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 73 MEA Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 74 MEA Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 75 MEA Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 76 MEA Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 77 MEA Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 78 MEA Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 79 MEA Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 80 Saudi Arabia Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 81 Turkey Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 82 UAE Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 83 South Africa Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 84 Rest of MEA Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) Table 85 Agreement As Key Business Strategies Adopted by Key Players in Direct-to-Patient Market Table 86 Contract As Key Business Strategies Adopted by Key Players in Direct-to-Patient Market Table 87 Expansion As Key Business Strategies Adopted by Key Players in Direct-to-Patient Market Table 88 Partnership As Key Business Strategies Adopted by Key Players in Direct-to-Patient Market Table 89 Launch As Key Business Strategies Adopted by Key Players in Direct-to-Patient Market Table 90 Access TeleCare: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 91 Access Telecare, .: Product Benchmarking Table 92 Access TeleCare, .: Strategic Outlook Table 93 AGNITY INC.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 94 AGNITY INC.: Product Benchmarking Table 95 AGNITY INC.: Strategic Outlook Table 96 AMD Global Telemedicine: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 97 AMD Global Telemedicine: Product Benchmarking Table 98 AMD Global Telemedicine: Strategic Outlook Table 99 American Well: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 100 American Well: Product Benchmarking Table 101 American Well: Strategic Outlook Table 102 Avel eCare: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 103 Avera e Care: Product Benchmarking Table 104 Avera e Care: Strategic Outlook Table 105 Axs Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 106 Axs Health: Product Benchmarking Table 107 Axs Healthcare: Strategic Outlook Table 108 Babylon Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 109 Babylon Health: Product Benchmarking Table 110 Babylon Health: Strategic Outlook Table 111 Citius Tech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 112 Citius Tech: Product Benchmarking Table 113 Citius Tech: Strategic Outlook Table 114 Dictum Health Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 115 Dictum Health Inc: Product Benchmarking Table 116 Dictum Health Inc: Strategic Outlook Table 117 Doctor Anywhere: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 118 Doctor Anywhere: Product Benchmarking Table 119 Doctor Anywhere: Strategic Outlook Table 120 Doctor on demand: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 121 Doctor on demand: Product Benchmarking Table 122 Doctor on demand: Strategic Outlook Table 123 Health Partners: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 124 Health Partners: Product Benchmarking Table 125 Health Partners: Strategic Outlook Table 126 Health Tap: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 127 Health Tap: Product Benchmarking Table 128 Health Tap: Strategic Outlook Table 129 HIMS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 130 HIMS: Product Benchmarking Table 131 HIMS: Strategic Outlook Table 132 Marken: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 133 Marken: Product Benchmarking Table 134 Marken: Strategic Outlook Table 135 20/20 NOW: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 136 20/20 NOW: Product Benchmarking Table 137 20/20 NOW: Strategic Outlook Table 138 NURX: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 139 NURX: Product Benchmarking Table 140 NURX: Strategic Outlook Table 141 Practo Technologies Pvt. Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 142 Practo Technologies Pvt Ltd: Product Benchmarking Table 143 Practo Technologies Pvt Ltd: Strategic Outlook Table 144 Specialists on call, Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 145 Specialists on call, Inc: Product Benchmarking Table 146 Specialists on call, Inc: Strategic Outlook Table 147 Teladoc Health Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 148 Teladoc Health Inc: Product Benchmarking Table 149 Teladoc Health Inc: Strategic Outlook Table 150 True pill: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 151 True pill: Product Benchmarking Table 152 True pill: Strategic Outlook Table 153 Up Script Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 154 Up Script Health: Product Benchmarking Table 155 Up Script Health: Strategic Outlook
List of Figures Figure 1 Schematics showing benefits of Direct-To-Patient Model Figure 2 Direct-to-Patient Market Segmentation Figure 3 Direct-to-Patient Market Forecast by Region: Market Attractiveness Index Figure 4 Direct-to-Patient Market by Type: Market Attractiveness Index Figure 5 Direct-to-Patient Market by Marketing: Market Attractiveness Index Figure 6 Direct-to-Patient Market by Health Services: Market Attractiveness Index Figure 7 Direct-to-Patient Market by Clinical Trials: Market Attractiveness Index Figure 8 Direct-to-Patient Market by Logistics: Market Attractiveness Index Figure 9 Direct-to-Patient Market by Therapeutics: Market Attractiveness Index Figure 10 Direct-to-Patient Market by Model: Market Attractiveness Index Figure 11 Direct-to-Patient Market: Market Dynamics Figure 12 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (V-Shaped Recovery Scenario) Figure 13 Direct-to-Patient Market Forecast by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (V-Shaped Recovery Scenario) Figure 14 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (W-Shaped Recovery Scenario) Figure 15 Direct-to-Patient Market Forecast by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (W-Shaped Recovery Scenario) Figure 16 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (U-Shaped Recovery Scenario) Figure 17 Direct-to-Patient Market Forecast by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (U-Shaped Recovery Scenario) Figure 18 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (L-Shaped Recovery Scenario) Figure 19 Direct-to-Patient Market Forecast by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (L-Shaped Recovery Scenario) Figure 20 Direct-to-Patient Market: Porter’s Five Forces Analysis Figure 21 Direct-to-Patient Market: PEST Analysis Figure 22 Direct-To-Patient Market by Type: Market Attractiveness Index Figure 23 Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%) Figure 24 Direct-To-Patient Market by Marketing: Market Attractiveness Index Figure 25 Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%)) Figure 26 Direct-to-Patient Market Forecast by Direct-to-Patient Health Services: Market Attractiveness Index Figure 27 Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%)) Figure 28 Direct-to-Patient Market Forecast by Clinical Trials: Market Attractiveness Index Figure 29 Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%)) Figure 30 Direct-To-Patient Market Forecast by Direct-to-Patient Logistics: Market Attractiveness Index Figure 31 Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%)) Figure 32 Direct-to-Patient Market Forecast by Therapeutics: Market Attractiveness Index Figure 33 Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%) Figure 34 Direct-to-Patient Market Forecast by Model: Market Attractiveness Index Figure 35 Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%) Figure 36 Direct-to-Patient Market Attractiveness Index by Region: Market Attractiveness Index Figure 37 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%)) Figure 38 Direct-to-Patient Market by Region, 2022-2032 (US$ Mn, AGR (%)) Figure 39 Direct-to-Patient Market Attractiveness Index by Region 2022, 2032 (Revenue, CAGR%) Figure 40 North America Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 41 North America Direct-to-Patient Market Share Forecast by Type 2022-2033 (%) Figure 42 North America Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR %) Figure 43 North America Direct-to-Patient Market Share Forecast by Marketing 2022-2032 (%) Figure 44 North America Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%)) Figure 45 North America Direct-to-Patient Market Share Forecast by Health Services 2022-2032 (%) Figure 46 North America Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%)) Figure 47 North America Direct-to-Patient Market Share Forecast by Clinical Trial 2023-2033 (%) Figure 48 North America Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%)) Figure 49 North America Direct-to-Patient Market Share Forecast by Logistics 2022-2032 (%) Figure 50 North America Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR %) Figure 51 North America Direct-to-Patient Market Share Forecast by Therapeutics 2022-2032 (%) Figure 52 North America Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%)) Figure 53 North America Direct-to-Patient Market Share Forecast by Model 2023-2033 (%) Figure 54 North America Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%)) Figure 55 North America Direct-to-Patient Market Share Forecast by Country 2023-2033 (%) Figure 56 U.S. Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 57 Canada Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 58 Europe Direct-to-Patient Market Attractiveness Index by Region Figure 59 Europe Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 60 Europe Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%)) Figure 61 Europe Direct-to-Patient Market Share Forecast by Type 2022-2032 (%) Figure 62 Europe Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%)) Figure 63 Europe Direct-to-Patient Market Share Forecast by Marketing 2022-2032 (%) Figure 64 Europe Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%)) Figure 65 Europe Direct-to-Patient Market Share Forecast by Health Services 2022-2032 (%) Figure 66 Europe Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%)) Figure 67 Europe Direct-to-Patient Market Share Forecast by Clinical Trials 2022-2032 (%) Figure 68 Europe Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%)) Figure 69 Europe Direct-to-Patient Market Share Forecast by Logistics 2022-2032 (%) Figure 70 Europe Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%)) Figure 71 Europe Direct-to-Patient Market Share Forecast by Therapeutics 2022-2032 (%) Figure 72 Europe Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%)) Figure 73 Europe Direct-to-Patient Market Share Forecast by Model 2022-2032 (%) Figure 74 Europe Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%)) Figure 75 Europe Direct-to-Patient Market Share Forecast by Country 2022-2032 (%) Figure 76 Germany Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 77 UK Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 78 France Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 79 Italy Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 80 Spain Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 81 Rest of Europe Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 82 Asia Pacific Direct-to-Patient Market Attractiveness Index by Region Figure 83 Asia-Pacific Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 84 Asia-Pacific Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR %)) Figure 85 Asia Pacific Direct-to-Patient Market Share Forecast by Type 2022-2032 (%) Figure 86 Asia-Pacific Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%)) Figure 87 Asia Pacific Direct-to-Patient Market Share Forecast by Marketing 2022-2032 (%) Figure 88 Asia-Pacific Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%)) Figure 89 Asia Pacific Direct-to-Patient Market Share Forecast by Health Services 2022-2032 (%) Figure 90 Asia-Pacific Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%)) Figure 91 Asia Pacific Direct-to-Patient Market Share Forecast by Clinical Trials 2022-2032 (%) Figure 92 Asia-Pacific Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%)) Figure 93 Asia Pacific Direct-to-Patient Market Share Forecast by Logistics 2022-2032 (%) Figure 94 Asia-Pacific Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%)) Figure 95 Asia Pacific Direct-to-Patient Market Share Forecast by Therapeutics 2022-2032 (%) Figure 96 Asia-Pacific Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%)) Figure 97 Asia Pacific Direct-to-Patient Market Share Forecast by Models 2022-2032 (%) Figure 98 Asia-Pacific Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR %)) Figure 99 Asia Pacific Direct-to-Patient Market Share Forecast by Country 2023-2033 (%) Figure 100 China Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 101 India Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 102 Japan Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 103 Australia Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 104 South Korea Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 105 Rest of Asia-Pacific Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 106 Latin America Direct-to-Patient Market Attractiveness Index by Region Figure 107 Latin America Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 108 Latin America Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%)) Figure 109 Latin America Direct-to-Patient Market Share Forecast by Type 2022-2032 (%) Figure 110 Latin America Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%)) Figure 111 Latin America Direct-to-Patient Market Share Forecast by Marketing 2022-2032 (%) Figure 112 Latin America Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%)) Figure 113 Latin America Direct-to-Patient Market Share Forecast by Health Services 2022-2032 (%) Figure 114 Latin America Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%)) Figure 115 Latin America Direct-to-Patient Market Share Forecast by Clinical Trials 2022-2032 (%) Figure 116 Latin America Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%)) Figure 117 Latin America Direct-to-Patient Market Share Forecast by Logistics 2022-2032 (%) Figure 118 Latin America Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%)) Figure 119 Latin America Direct-to-Patient Market Share Forecast by Therapeutics 2022-2032 (%) Figure 120 Latin America Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%)) Figure 121 Latin America Direct-to-Patient Market Share Forecast by Model 2023-2033 (%) Figure 122 Latin America Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%)) Figure 123 Latin America Direct-to-Patient Market Share Forecast by country 2023-2033 (%) Figure 124 Brazil Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 125 Mexico Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 126 Rest of Latin America Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 127 MEA Direct-to-Patient Market Attractiveness Index by Region Figure 128 MEA Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 129 MEA Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%)) Figure 130 MEA Direct-to-Patient Market Share Forecast by Type 2022-2032 (%) Figure 131 MEA Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%)) Figure 132 MEA Direct-to-Patient Market Share Forecast by Marketing 2022-2032 (%) Figure 133 MEA Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%)) Figure 134 MEA Direct-to-Patient Market Share Forecast by Health Services 2022-2032 (%) Figure 135 MEA Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%)) Figure 136 MEA Direct-to-Patient Market Share Forecast by Clinical Trial 2022-2032 (%) Figure 137 MEA Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%)) Figure 138 MEA Direct-to-Patient Market Share Forecast by Logistics 2022-2032 (%) Figure 139 MEA Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%)) Figure 140 MEA Direct-to-Patient Market Share Forecast by Therapeutics 2022-2032 (%) Figure 141 MEA Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%)) Figure 142 MEA Direct-to-Patient Market Share Forecast by Model 2022-2032 (%) Figure 143 MEA Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%)) Figure 144 MEA Direct-to-Patient Market Share Forecast by Country 2022-2032 (%) Figure 145 Saudi Arabia Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 146 Turkey Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 147 UAE Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 148 South Africa Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 149 Rest of MEA Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%)) Figure 150 American Well: Net Revenue, 2018-2021 (US$ million, AGR (%)) Figure 151 American Well: Operating Income 2018-2021 (US$ million, AGR (%)) Figure 152 American Well: Research & Development Expenses 2018-2021 (US$ million, AGR (%)) Figure 153 Babylon Health: Net Revenue, 2019-2021 (US$ million, AGR%) Figure 154 Babylon Health: Operating Income, 2019-2021 (US$ million, AGR%) Figure 155 Babylon Health: R&D Expenses 2019-2021 (US$ million, AGR%) Figure 156 Health Partners: Net Revenue, 2018-2020 (US$ million, AGR (%)) Figure 157 Health Partners: Operating Income, 2018-2020 (US$ million, AGR (%)) Figure 158 HIMS: Net Revenue, 2019-2021 (US$ million, AGR (%)) Figure 159 HIMS: R&D Expenses, 2019-2021 (US$ million, AGR (%)) Figure 160 Specialists on call, Inc: Revenue, 2019-2021 (US$ million, AGR (%)) Figure 161 Specialists on call, Inc: R&D Expense 2019-2021 (US$ million, AGR%) Figure 162 Teladoc, Health Inc: Revenue, 2017-2021 (US$ million, AGR (%)) Figure 163 Teladoc, Health Inc: Operating Income, 2017-2021 (US$ million, AGR(%)) Figure 164 Teladoc, Health Inc Research & Development Expenses 2017-2021 (US$ million, AGR (%))
List of Companies Profiled in the report Access TeleCare Agnity Inc. AMD Global Telemedicine American Well Avel eCare Axs Health Babylon Health Citius Tech Dictum Health Inc. Doctor Anywhere Doctor on Demand Health Partners Health Tap HIMS Marken 20/20 NOW NURX Practo Technologies Pvt. Ltd. Specialists on call, Inc. Teladoc Health Inc. True pill Up Script Health
List of Other Companies Mentioned in the report Antidote Athenahealth, Inc. AutoCruitment BBK Worldwide Cerner Corporation Clariness ClinicalConnection CSSi Curavit Elligo Health Research Getwell Network, Inc. IBM Lincor Solutions McKesson Corporation Medecision, Inc. MMG Orion Health Ltd. Phytel Inc. Praxis Science37 StudyKik TrialSpark TrialX Welvu Yourcareuniverse, Inc.
List of Associations Mentioned in the Report Africa Centres for Disease Control and Prevention (Africa CDC) American Association of Medical Colleges (AAMC) Astar's Genome institute of Singapore (GIS) Biotechnology Industry Research Assistance council (BIRAC) Clinical Laboratory Improvement Amendments (CLIA) Clinical Laboratory Improvement Amendments (CLIA) Diagnostic Related Group (DRG) Food and Drug Administration (FDA) Indian Department of Biotechnology (DBT) Indian institute of technology (IIT) Indian Medical Device Industry (AIMED) International Diabetes Federation (IDF) International Organisation for Standardisation (ISO) The Foundation for Innovative New Diagnostics (FIND) World health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Direct-to-Patient Market Report 2022-2032
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
Visiongain Publishes Deep Frozen Packaging Logistics Market Report 2023-2033
The global Deep Frozen Packaging Logistics market was valued at US$21,088.3 million in 2022 and is projected to grow at a CAGR of 7.7% during the forecast period 2023-2033.
Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033
The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
